Trial reportBMC oral health2021
Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial.
Trial report in BMC oral health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Antioxidant therapy for patients with oral lichen planus: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Efficacy of traditional Chinese Medicine-based biological extracts in the treatment of oral lichen planus.Frontiers in cellular and infection microbiology · 2026Article
- Vitamin C in Oral Lichen Planus: Pathobiological Rationale and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Metabolically engineered plant cell cultures as biofactories for the production of high-value carotenoids astaxanthin and canthaxanthin.Scientific reports · 2025Article
- A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy.Food science & nutrition · 2025Review
- Oxidative Stress and Salivary Physicochemical Characteristics Relative to Dental Caries and Restorative Treatment in Children.Antioxidants (Basel, Switzerland) · 2025Article
- Emerging functions of lycopene in the management of digestive premalignant lesions.Frontiers in pharmacology · 2024Review
- Effect of zinc supplementation as an adjuvant to corticosteroid treatment in patients with oral lichen planus: A systematic review.Journal of advanced periodontology & implant dentistry · 2023Article
- Sustainable Valorization of Tomato By-Products to Obtain Bioactive Compounds: Their Potential in Inflammation and Cancer Management.Molecules (Basel, Switzerland) · 2022Review
- Recent insights into the biological and pharmacological activity of lycopene.EXCLI journal · 2022Article
- Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches.Oxidative medicine and cellular longevity · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral lichen planus is an autoimmune disease in which topical steroids are the first line of treatment. The adverse effects of systemic corticosteroids prescribed for resistant oral lichen planus cases advocate alternative modalities. Lycopene is an antioxidant with a wide range of beneficial properties. This trial aimed to evaluate the effect of pure lycopene as compared to systemic corticosteroids (Prednisolone) on the symptoms, signs and oxidative stress in patients with erosive oral lichen planus recalcitrant to topical steroids.
methodsTwenty patients were randomly divided into the test (lycopene) and control (corticosteroids) groups. Numeric rating scale and Escudier et al. (Br J Dermatol 4:765-770, 2007. https://doi.org/10.1111/j.1365-2133.2007.08106.x ) lesion scores were assessed at baseline and weeks 4 and 8 from baseline. Serum levels of 8-isoprostane were measured in all patients at baseline and at the end of treatment (week 8).
resultsThere was a significant reduction in signs and symptoms after the end of treatment in each group. However, no significant difference was found between the lycopene and the corticosteroids group. Moreover, a significant reduction in 8-isoprostane levels was observed in the lycopene group from baseline and as compared to the control group.
conclusionsBased on the study results, lycopene is a safe and effective therapeutic modality for resistant oral lichen planus. 8-isoprostane is a biomarker of lipid peroxidation that can be reduced by lycopene. Trial registration ID: PACTR202003484099670. 'Retrospectively registered on 11/3/2020'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.